Murae Organisor Ltd
₹ 1.48
-1.99%
06 May
- close price
About
Incorporated in 2012, Earum Pharmaceuticals Ltd manufactures and trades in pharma products[1]
Key Points
- Market Cap ₹ 36.6 Cr.
- Current Price ₹ 1.48
- High / Low ₹ 3.10 / 0.90
- Stock P/E
- Book Value ₹ 2.21
- Dividend Yield 0.00 %
- ROCE 11.7 %
- ROE 11.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.67 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -16.8% over past five years.
- Company has a low return on equity of 8.98% over last 3 years.
- Company has high debtors of 217 days.
- Working capital days have increased from 450 days to 698 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 8.83 | 18.57 | 23.34 | 35.42 | 50.70 | 55.11 | 41.08 | 21.04 | 14.09 | 4.07 | |
0.00 | 0.00 | 8.62 | 18.06 | 22.91 | 33.85 | 47.40 | 53.87 | 48.84 | 25.46 | 13.16 | 4.41 | |
Operating Profit | 0.00 | 0.00 | 0.21 | 0.51 | 0.43 | 1.57 | 3.30 | 1.24 | -7.76 | -4.42 | 0.93 | -0.34 |
OPM % | 2.38% | 2.75% | 1.84% | 4.43% | 6.51% | 2.25% | -18.89% | -21.01% | 6.60% | -8.35% | ||
0.00 | 0.00 | 0.01 | 0.06 | 0.35 | 0.41 | 0.05 | 2.27 | 8.93 | 7.70 | 2.26 | 0.66 | |
Interest | 0.00 | 0.00 | 0.06 | 0.39 | 0.52 | 0.72 | 1.04 | 0.97 | 0.93 | 0.08 | 0.29 | 0.42 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.04 | 0.10 | 0.12 | 0.12 | 0.10 | 0.09 |
Profit before tax | 0.00 | 0.00 | 0.16 | 0.16 | 0.24 | 1.24 | 2.27 | 2.44 | 0.12 | 3.08 | 2.80 | -0.19 |
Tax % | 31.25% | 43.75% | 33.33% | 26.61% | 27.31% | 25.82% | 25.00% | 27.92% | 28.93% | |||
0.00 | 0.00 | 0.11 | 0.10 | 0.16 | 0.91 | 1.66 | 1.82 | 0.09 | 2.22 | 1.98 | -0.34 | |
EPS in Rs | 0.00 | 0.00 | 1.10 | 0.20 | 0.32 | 0.61 | 1.11 | 0.06 | 0.00 | 0.07 | 0.06 | -0.03 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -17% |
3 Years: | -37% |
TTM: | -76% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 3% |
TTM: | -132% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -36% |
1 Year: | -33% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 12% |
3 Years: | 9% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.01 | 0.11 | 0.11 | 0.31 | 0.31 | 6.17 | 6.17 | 12.34 | 12.34 | 49.42 |
Reserves | 0.00 | 0.00 | 0.86 | 1.26 | 1.42 | 4.61 | 5.64 | 8.25 | 8.33 | 4.39 | 6.37 | 5.22 |
0.00 | 0.00 | 1.14 | 1.90 | 2.06 | 7.21 | 9.58 | 9.28 | 11.33 | 8.74 | 8.74 | 2.52 | |
0.00 | 0.00 | 2.54 | 5.51 | 7.49 | 7.38 | 7.73 | 12.45 | 2.04 | 3.33 | 1.14 | 3.35 | |
Total Liabilities | 0.01 | 0.01 | 4.55 | 8.78 | 11.08 | 19.51 | 23.26 | 36.15 | 27.87 | 28.80 | 28.59 | 60.51 |
0.00 | 0.00 | 0.04 | 0.17 | 0.16 | 0.20 | 0.48 | 0.80 | 0.76 | 0.58 | 0.48 | 0.44 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.03 | 0.00 | 0.00 | 0.00 | 0.00 |
0.01 | 0.01 | 4.51 | 8.61 | 10.92 | 19.31 | 22.78 | 32.32 | 27.11 | 28.22 | 28.11 | 60.07 | |
Total Assets | 0.01 | 0.01 | 4.55 | 8.78 | 11.08 | 19.51 | 23.26 | 36.15 | 27.87 | 28.80 | 28.59 | 60.51 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | -1.80 | -0.26 | 0.09 | -7.09 | -0.48 | -3.45 | -7.10 | 2.61 | 0.26 | |
0.00 | 0.00 | -0.04 | -0.15 | -0.02 | -0.05 | -0.32 | -3.45 | 2.94 | 0.06 | 0.00 | |
0.00 | 0.00 | 1.84 | 0.77 | -0.25 | 6.98 | 0.94 | 6.76 | 2.90 | -2.67 | -0.29 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.35 | -0.18 | -0.16 | 0.14 | -0.14 | -1.26 | -0.01 | -0.03 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 124.84 | 87.47 | 55.99 | 111.19 | 78.11 | 112.26 | 94.80 | 260.91 | 217.34 | ||
Inventory Days | 70.52 | 77.88 | 108.46 | 91.19 | 86.30 | 97.05 | 121.96 | 178.56 | 391.86 | ||
Days Payable | 112.93 | 107.21 | 82.75 | 77.11 | 53.85 | 83.42 | 10.18 | 17.64 | -25.37 | ||
Cash Conversion Cycle | 82.43 | 58.13 | 81.69 | 125.27 | 110.56 | 125.89 | 206.58 | 421.84 | 634.57 | ||
Working Capital Days | 81.43 | 54.05 | 57.71 | 115.72 | 98.27 | 125.91 | 222.31 | 430.92 | 698.14 | ||
ROCE % | 0.00% | 21.78% | 20.83% | 22.16% | 24.94% | 23.93% | 17.38% | 4.24% | 12.32% | 11.68% |
Documents
Announcements
- Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended On 31St March, 2024 29 Apr
- Submission Of Certificate Under Regulation 40(9) Read With Regulation 40(10) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended On 31St March, 2024 27 Apr
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 25 Apr
- Shareholder Meeting / Postal Ballot-Outcome of EGM 24 Apr
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Apr - Newspaper Advertisement for Addendum to Notice of the EGM of Murae Organisor Limited
Business Overview:[1]
Company is in the pharmaceutical business handling marketing, trading and distribution of a wide range of pharmaceutical formulation products, of which 120 products are marketed by company under its own brand, and their manufacturing is outsourced to third parties. Apart from this, company also trades in active pharmaceutical ingredients